DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Champignon Brands Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Champignon Brands Inc. ("Champignon" or "the Company") (OTC Pink: SHRMF) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between March 27, 2020 and February 17, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before June 9, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Champignon failed to maintain sufficient internal controls over financials. The Company's issued financial statements were false and could not be relied upon, and required restatement. The Company engaged in acquisitions with undisclosed third parties. As a result, the British Columbia Securities Commission would suspend the Company from trading. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Champignon, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE:

The Schall Law Firm

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/86853

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Dried mushrooms and capsules aligned on a light surface.

Psychedelics Market Update: H1 2025 in Review

The market for psychedelic drugs is emerging as a strategic investment opportunity in healthcare, with forecasts generally placing its value at around US$6.4 billion in 2025. This burgeoning sector is set for robust, double-digit compound annual growth, significantly driven by North America,... Keep Reading...
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry. However, the sector is seeing a resurgence of optimism in 2025 on the back of various... Keep Reading...

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass management will host a conference call at 8:00 am ET (1:00pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth... Keep Reading...
"2023 year-end review" text overlaid on image of psychedelic mushrooms.

Psychedelics Market 2023 Year-End Review

The psychedelics industry is maturing after the investment boom of 2020 and 2021, and patient long-term investors looking for opportunities to diversify their portfolios have options when it comes to exposure. As clinical trials and research continue to demonstrate the potential benefits of... Keep Reading...
Glowing pyschedelic mushrooms.

How to Invest in Psychedelics

Market participants are wondering how to invest in psychedelics as the opportunity attached to these drugs grows.Promising research associated with psychedelic medicine shows the potential for these products to treat mental health issues and even addiction to opioids. “(Psychedelic)-assisted... Keep Reading...
A colorful brain illustrating brain on pyschedelics.

Psychedelics Stocks to Watch

The small-cap market has been invaded by a flurry of psychedelics stocks to watch thanks to new company launches. Investors now have a variety of options for taking a run in the shroom stocks space.In an effort to expand the capabilities of the medical field, companies are starting to... Keep Reading...

Interactive Chart

Latest Press Releases

Related News